Zepbound® Subcutaneous Injection 2.5mg/5mg/7.5mg/10mg/12.5mg/15mg ATEOS®

  If needed, please contact customer service at the bottom right corner.

Mandatory Warnings (⚠️ Must Confirm)

1. This product is a prescription drug. Sale and use without a physician’s prescription are prohibited! The purchaser shall bear all health damages and legal liabilities caused by unauthorized purchase or use.
2. Use for non-medical purposes (e.g., general weight loss, cosmetic slimming) is prohibited! Off-label use may cause severe side effects such as pancreatitis and hypoglycemic shock.
3. E-commerce platforms only display product information and do not provide medication advice! All medication decisions must be made by a physician based on the patient’s medical history and test results. The platform is not liable for the efficacy or safety of medication use.
4. Sale to children, pregnant women, lactating women, and contraindicated populations is prohibited! If non-compliant orders are found, the platform will cancel the order and may report to regulatory authorities.
5. Failure to store according to specified conditions (e.g., freezing, exposure to high temperatures) may cause drug inactivation! Before use, confirm that the solution is clear and free of turbidity or precipitation; do not inject deteriorated drugs.
6. If using other medications (especially insulin, antidiabetic drugs, or antihypertensive drugs), inform the physician in advance to avoid drug interactions (e.g., increased risk of hypoglycemia).

1. Indications (Efficacy/Effects)

1. Have hypertension, dyslipidemia, or Type 2 diabetes;
2. Have not achieved sufficient effects with diet and exercise therapy;
3. Meet either of the following BMI standards:
   • Body Mass Index (BMI) ≥27kg/m² with ≥2 obesity-related health disorders;
   • Body Mass Index (BMI) ≥35kg/m²

2. Dosage and Administration

1. For adults, the usual starting dose is 2.5mg of Tirzepatide administered subcutaneously once weekly. The dose is increased by 2.5mg at 4-week intervals, with a regular maintenance dose of 10mg once weekly.
2. Dose adjustment may be made based on the patient’s condition:
   • Dose reduction: Minimum dose of 5mg once weekly;
   • Dose increase: Increase by 2.5mg once weekly at intervals of 4 weeks or longer, up to a maximum dose of 15mg once weekly;
3. Injection sites: Abdomen, outer thigh, or outer upper arm are recommended. It is advised to rotate injection sites each time to avoid repeated injections in the same area.
4. Administration time: It is recommended to administer on the same day and at the same time each week (no need to align with meal times).

3. Contraindications (Patients for Whom Administration is Prohibited)

1. Patients with a history of hypersensitivity to the components of this drug;
2. Patients with diabetic ketoacidosis, diabetic coma or pre-coma, or Type 1 diabetes (immediate treatment with insulin preparations is essential);
3. Patients with Type 2 diabetes in emergency situations such as severe infections or surgery (blood glucose management with insulin preparations is recommended).

4. Precautions

4.1 Medication Safety

• Use only under the diagnosis and prescription of a physician. Do not adjust the dose or discontinue use without authorization.
• Gastrointestinal adverse events such as nausea, vomiting, constipation, diarrhea, and fatigue may occur. If symptoms are severe or persistent, consult a physician immediately.
• Hypoglycemia may occur (especially when used in combination with insulin or other antidiabetic drugs). If symptoms such as dizziness, palpitations, or cold sweats appear, supplement with sugar (e.g., sugar water, candy) promptly. Seek medical attention if symptoms do not improve.
• Patients with a history of medullary thyroid carcinoma or pancreatitis must inform the physician in detail before use.

4.2 Administration to Special Populations

• Pregnant women or women planning to become pregnant: Contraindicated (may affect fetal development);
• Lactating women: Contraindicated (drug may pass into breast milk and affect infants);
• Pediatric patients (under 18 years old): Contraindicated (no clinical data available);
• Patients with hepatic or renal impairment: Physicians will assess medication based on hepatic/renal function indicators (e.g., estimated Glomerular Filtration Rate [eGFR]); caution is advised for patients with severe impairment.

4.3 Storage & Transportation

• Unopened products: Store in a refrigerated environment at 2–8°C (36–46°F), protected from light (e.g., keep in the original packaging carton).
• If refrigeration is not possible: May be stored at room temperature (not exceeding 30°C/86°F) for a short period, but for no longer than 21 days.
• Freezing prohibition: Do not freeze the product, as freezing will cause loss of efficacy. Even if thawed, the product must be discarded and not used.
• During transportation: If the temperature exceeds 30°C, use an insulated bag with ice packs to control temperature and avoid direct sunlight.
• In-flight carrying: Apply for an English medication certificate from a physician in advance and confirm with the airline.